132 related articles for article (PubMed ID: 29769205)
1. Playing the Melanoma Endgame.
Teh JLF; Aplin AE
Clin Cancer Res; 2018 Oct; 24(19):4629-4630. PubMed ID: 29769205
[TBL] [Abstract][Full Text] [Related]
2. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Gide TN; Wilmott JS; Scolyer RA; Long GV
Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
4. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
Katz H; Wassie E; Alsharedi M
Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Immunotherapy: Picking a Winner.
Teng MW; Khanna R; Smyth MJ
Cancer Discov; 2016 Aug; 6(8):818-20. PubMed ID: 27485001
[TBL] [Abstract][Full Text] [Related]
7. Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma?
Pawelec G
Clin Cancer Res; 2018 Nov; 24(21):5193-5194. PubMed ID: 29907623
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.
Sanlorenzo M; Vujic I; Moy A; Quaglino P; Fierro MT; Gammaitoni L; Carnevale-Schianca F; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2015; 15(10):1491-500. PubMed ID: 26206099
[TBL] [Abstract][Full Text] [Related]
10. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
11. Forestalling BRAF-Inhibitor Resistance in a Shocking Way.
Sullivan RJ
Clin Cancer Res; 2018 Nov; 24(22):5496-5498. PubMed ID: 29980533
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
13. Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells.
Kiessling R; Mao Y; Pico de Coaña Y
Clin Cancer Res; 2014 Mar; 20(6):1401-3. PubMed ID: 24526737
[TBL] [Abstract][Full Text] [Related]
14. Seeking Synergy of Checkpoint Blockade through TGFβ Inhibition.
Puré E
Cancer Immunol Res; 2018 Dec; 6(12):1444. PubMed ID: 30510056
[TBL] [Abstract][Full Text] [Related]
15. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
Aris M; Barrio MM
Front Immunol; 2015; 6():46. PubMed ID: 25709607
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.
O'reilly A; Larkin J
Expert Rev Anticancer Ther; 2017 Jul; 17(7):647-655. PubMed ID: 28604130
[TBL] [Abstract][Full Text] [Related]
17. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
18. Emerging targeted therapies for melanoma.
Johnson DB; Pollack MH; Sosman JA
Expert Opin Emerg Drugs; 2016 Jun; 21(2):195-207. PubMed ID: 27148822
[TBL] [Abstract][Full Text] [Related]
19. Genomic Approaches to Understanding Response and Resistance to Immunotherapy.
Braun DA; Burke KP; Van Allen EM
Clin Cancer Res; 2016 Dec; 22(23):5642-5650. PubMed ID: 27698000
[TBL] [Abstract][Full Text] [Related]
20. Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma.
Christiansen SA; Khan S; Gibney GT
Cancer J; 2017; 23(1):59-62. PubMed ID: 28114256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
